Constitutive activation of NF-κB in human hepatocellular carcinoma: Evidence of a cytoprotective role

Human Gene Therapy

Volumn 17, Issue 3, 2006, Pages 280-290

  Qiao, Liang ^a,b   Zhang, Hongxia ^a   Yu, Jun ^a,c   Francisco, Rona ^a   Dent, Paul ^d   Ebert, Matthias P A ^e   Röcken, Christoph ^f   Farrell, Geoffrey ^a,g  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

^c CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^d VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^f CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^g CANBERRA HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ACTIN; BETA GALACTOSIDASE; CASPASE 3; HYDROGEN PEROXIDE; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MONOMER; SYNAPTOTAGMIN;

ADENOVIRUS; APOPTOSIS; ARTICLE; CELL GROWTH; CELL KILLING; CELL PROLIFERATION; CELL PROTECTION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOTOXICITY; DRUG MECHANISM; DRUG POTENCY; ENZYME ACTIVITY; EXPOSURE; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CELL CARCINOMA; MUTANT; OXIDATIVE STRESS; PROTEIN DNA BINDING; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SENSITIZATION; VIRUS RECOMBINANT;

ADENOVIRIDAE; APOPTOSIS; BETA-GALACTOSIDASE; CARCINOMA, HEPATOCELLULAR; CASPASE 3; CASPASES; CELL PROLIFERATION; CYTOPROTECTION; DNA; HUMANS; HYDROGEN PEROXIDE; I-KAPPA B PROTEINS; LIVER; LIVER NEOPLASMS; NF-KAPPA B; OXIDANTS; OXIDATIVE STRESS; PROTEIN TRANSPORT; TUMOR CELLS, CULTURED;

ADENOVIRIDAE;

EID: 33645457576     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.2006.17.280     Document Type: Article

References (60)

1. ARLT, A., VORNDAMM, J., BREITENBROUCH, M., FOLSCH, U.R., KALTHOFF, H., SCHMIDT, W.E., and SCHAFER, H. (2001). Inhibition of NF-κB sensitizes human pancreatic carcinoma cells to apoptosis induced by etoposide (VP16) or doxorubicin. Oncogene 20, 859-868.
2. BALKWILL, F., and COUSSENS, L.M. (2004). Cancer: An inflammatory link. Nature 431, 405-406.
3. BANTEL, H., and SCHULZE-OSTHOFF, K. (2003). Apoptosis in hepatitis C virus infection. Cell Death Differ. 10, S48-S58.
4. BARKETT, M., and GILMORE, T.D. (1999). Control of apoptosis by Rel/NF-κB transcription factors. Oncogene 18, 6910-6924.
5. BENTIRES-ALJ, M., HELLIN, A.C., AMEYAR, M., CHOUAIB, S., MERVILLE, M.P., and BOURS, V. (1999). Stable inhibition of nuclear factor κB in cancer cells does not increase sensitivity to cytotoxic drugs. Cancer Res. 59, 811-815.
6. BIRBACH, A., GOLD, P., BINDER, B.R., HOFER, E., DE MARTIN, R., and SCHMID, J.A. (2002). Signaling molecules of the NF-κB pathway shuttle constitutively between cytoplasm and nucleus. J. Biol. Chem. 277, 10842-10851.
7. BIRD, M.A., BLACK, D., LANGE, P.A., SAMSON, C.M., HAYDEN, M., and BEHRNS, K.E. (2003). NF-κB inhibition decreases hepatocyte proliferation but does not alter apoptosis in obstructive jaundice. J. Surg. Res. 114, 110-117.
8. BROWN, K., GERSTBERGER, S., CARLSON, L., FRANZOSO, G., and SIEBENLIST, U. (1995). Control of IκBα proteolysis by site-specific, signal-induced phosphorylation. Science 267, 1485-1488.
9. CAI, Z., KORNER, M., TARANTINO, N., and CHOUAIB, S. (1997). IκBα over-expression in human breast carcinoma MCF7 cells inhibits nuclear factor-κB activation but not tumor necrosis factor α-induced apoptosis. J. Biol. Chem. 272, 96-101.
10. CHEN, G.Q., ZHOU, L., STYBLO, M., WALTON, F., JING, Y., WEINBERG, R., CHEN, Z., and WAXMAN, S. (2003). Methylated metabolites of arsenic trioxide are more potent than arsenic trioxide as apoptotic but not differentiation inducers in leukemia and lymphoma cells. Cancer Res. 63, 1853-1859.
11. CHIAO, P.J., NA, R., NIU, J., SCLABAS, G.M., DONG, Q., and CURLEY, S.A. (2002). Role of Rel/NF-κB transcription factors in apoptosis of human hepatocellular carcinoma cells. Cancer 95, 1696-1705.
12. DAI, Y., PEI, X.Y., RAHMANI, M., CONRAD, D.H., DENT, P., and GRANT, S. (2004). Interruption of the NF-κB pathway by Bay 11-7082 promotes UCN-01-mediated mitochondrial dysfunction and apoptosis in human multiple myeloma cells. Blood 103, 2761-2770.
13. DEBATIN, K.M. (2004). Apoptosis pathways in cancer and cancer therapy. Cancer Immunol. Immunother. 53, 153-159.
14. EL-HASSAN, H., ANWAR, K., MACANAS-PIRARD, P., CRABTREE, M., CHOW, S.C., JOHNSON, V.L., LEE, P.C., HINTON, R.H., PRICE, S.C., and KASS, G.E. (2003). Involvement of mitochondria in acetaminophen-induced apoptosis and hepatic injury: Roles of cytochrome c, Bax, Bid, and caspases. Toxicol. Appl. Pharmacol. 191, 118-129.
15. EL-SERAG, H.B., and MASON, A.C. (1999). Rising incidence of hepatocellular carcinoma in the United States. N. Engl. J. Med. 340, 745-750.
16. FEIG, B.W., LU, X., HUNT, K.K., SHAN, Q., YU, D., POLLOCK, R., and CHIAO, P. (1999). Inhibition of transcription factor nuclear factor-κB by adenoviral-mediated expression of IκBαM results in tumor cell death. Surgery 126, 399-405.
17. GRETEN, F.R., and KARIN, M. (2004). The IKK/NF-κB activation pathway: A target for prevention and treatment of cancer. Cancer Lett. 206, 193-199.
18. GUO, L.L., XIAO, S., and GUO, Y. (2005). Activation of transcription factors NF-κB and AP-1 and their relations with apoptosis associated-proteins in hepatocellular carcinoma. World J. Gastroenterol. 11, 3860-3865.
19. HEIMBERG, H., HEREMANS, Y., JOBIN, C., LEEMANS, R., CARDOZO, A.K., DARVILLE, M., and EIZIRIK, D.L. (2001). Inhibition of cytokine-induced NF-κB activation by adenovirus-mediated expression of a NF-κB super-repressor prevents β-cell apoptosis. Diabetes 50, 2219-2224.
20. HELLERBRAND, C., JOBIN, C., IIMURO, Y., LICATO, L., SARTOR, R.B., and BRENNER, D.A. (1998). Inhibition of NF-κB in activated rat hepatic stellate cells by proteasome inhibitors and an IκB super-repressor. Hepatology 27, 1285-1295.
21. HENKEL, T., MACHLEIDT, T., ALKALAY, I., KRONKE, M., BENNERIAH, Y., and BAEUERLE, P.A. (1993). Rapid proteolysis of IκB-α is necessary for activation of transcription factor NF-κB. Nature 365, 82-85.
22. HERR, I., and DEBATIN, K.M. (2001). Cellular stress response and apoptosis in cancer therapy. Blood 98, 2603-2614.
23. HYODO, I., JINNO, K., TANIMIZU, M., DOI, T., NISHIKAWA, Y., HOSOKAWA, Y., and MORIWAKI, S. (1996). Intercellular adhesion molecule-1 release from human hepatocellular carcinoma. Cancer Detect. Prev. 20, 308-315.
24. IIMURO, Y., NISHIURA, I., HELLERBRAND, C., BEHRNS, K.E., SCHOONHOVEN, R., GRISHAM, J.W., and BRENNER, D.A. (1998). NF-κB prevents apoptosis and liver dysfunction during liver regeneration. J. Clin. Invest. 101, 802-811.
25. JOBIN, C., PANJA, A., HELLERBRAND, C., IIMURO, Y., DIDONATO, J., BRENNER, D.A., and SARTOR, R.B. (1998). Inhibition of proinflammatory molecule production by adenovirus-mediated expression of a nuclear factor κB super-repressor in human intestinal epithelial cells. J. Immunol. 160, 41041-41048.
26. KARIN, M. (1999). How NF-κB is activated: The role of the IκB kinase (IKK) complex. Oncogene 18, 6867-6874.
27. KARIN, M., and GRETEN, F.R. (2005). NF-κB: Linking inflammation and immunity to cancer development and progression. Nat. Rev. Immunol. 5, 749-759.
28. KARIN, M., and LIN, A. (2002). NF-κB at the crossroads of life and death. Nat. Immunol. 3, 221-227.
29. KAUFMANN, S.H., and EARNSHAW, W.C. (2000). Induction of apoptosis by cancer chemotherapy. Exp. Cell Res. 256, 42-49.
30. KUCHARCZAK, J., SIMMONS, M.J., FAN, Y., and GELINAS, C. (2003). To be, or not to be: NF-κB is the answer-role of Rel/NF-κB in the regulation of apoptosis. Oncogene 22, 8961-8982.
31. LAW, M.G., ROBERTS, S.K., DORE, G.J., and KALDOR, J.M. (2000). Primary hepatocellular carcinoma in Australia, 1978-1997: Increasing incidence and mortality. Med. J. Aust. 173, 403-405.
32. LI, Q., WITHOFF, S., and VERMA, I.M. (2005). Inflammation-associated cancer: NF-κB is the lynchpin. Trends Immunol. 26, 318-325.
33. LI, Y., ZHANG, W., MANTELL, L.L., KAZZAZ, J.A., FEIN, A.M., and HOROWITZ, S. (1997). Nuclear factor-κB is activated by hyperoxia but does not protect from cell death. J. Biol. Chem. 272, 20646-20649.
34. LUO, J.L., MAEDA, S., HSU, L.C., YAGITA, H., and KARIN, M. (2004). Inhibition of NF-κB in cancer cells converts inflammation-induced tumor growth mediated by TNFα to TRAIL-mediated tumor regression. Cancer Cell 6, 297-305.
35. MAEDA, S., KAMATA, H., LUO, J.L., LEFFERT, H., and KARIN, M. (2005). IKKβ couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis. Cell 121, 977-990.
36. MONKS, N.R., BISWAS, D.K., and PARDEE, A.B. (2004). Blocking anti-apoptosis as a strategy for cancer chemotherapy: NF-κB as a target. J. Cell. Biochem. 92, 646-650.
37. PALOMBELLA, V.J., RANDO, O.J., GOLDBERG, A.L., and MANIATIS, T. (1994). The ubiquitin-proteasome pathway is required for processing the NF-κB precursor protein and the activation of NF-κB. Cell 78, 773-785.
38. PANWALKAR, A., VERSTOVSEK, S., and GILES, F. (2004). Nuclear factor-κB modulation as a therapeutic approach in hematologic malignancies. Cancer 100, 1578-1589.
39. PATEL, N.M., NOZAKI, S., SHORTLE, N.H., BHAT-NAKSHATRI, P., NEWTON, T.R., RICE, S., GELFANOV, V., BOSWELL, S.H., GOULET, R.J., SLEDGE, G.W., JR., and NAKSHATRI, H. (2000). Paclitaxel sensitivity of breast cancer cells with constitutively active NF-κB is enhanced by IκBα super-repressor and parthenolide. Oncogene 19, 4159-4169.
40. PIKARSKY, E., PORAT, R.M., STEIN, I., ABRAMOVITCH, R., AMIT, S., KASEM, S., GUTKOVICH-PYEST, E., URIELISHOVAL, S., GALUN, E., and BEN-NERIAH, Y. (2004). NF-κB functions as a tumour promoter in inflammation-associated cancer. Nature 431, 461-466.
41. PLUMPE, J., MALEK, N.P., BOCK, C.T., RAKEMANN, T., MANNS, M.P., and TRAUTWEIN, C. (2000). NF-κB determines between apoptosis and proliferation in hepatocytes during liver regeneration. Am. J. Physiol. Gastrointest. Liver Physiol. 278, G173-Gl83.
42. Kip-1 in primary mouse hepatocytes, leading to reduced cell cycle progression. Hepatology 34, 906-917.
43. QIAO, L., MCKINSTRY, R., GUPTA, S., GILFOR, D., WINDLE, J.J., HYLEMON, P.B., GRANT, S., FISHER, P.B., and DENT, P. (2002). Cyclin kinase inhibitor p21 potentiates bile acid-induced apoptosis in hepatocytes that is dependent on p53. Hepatology 36, 39-48.
44. QIAO, L., YU, J., DENT, P., and FARRELL, G. (2005). NF-κB protects rat ARL-6 hepatocellular carcinoma cells against hydrogen peroxide-induced apoptosis. Cancer Biol. Ther. 4, 1195-1202.
45. RAYET, B., and GELINAS, C. (1999). Aberrant rel/nfkb genes and activity in human cancer. Oncogene 18, 6938-6947.
46. SAMANTA, A.K., HUANG, H.J., BAST, R.C., Jr., and LlAO, W.S. (2004). Overexpression of MEKK3 confers resistance to apoptosis through activation of NF-κB. J. Biol. Chem. 279, 7576-7583.
47. SATO, T., ODAGIRI, H., IKENAGA, S.K., MARUYAMA, M., and SASAKI, M. (2003). Chemosensitivity of human pancreatic carcinoma cells is enhanced by IκBα super-repressor. Cancer Sci. 94, 467-472.
48. SCHRECK, R., RIEBER, P., and BAEUERLE, P.A. (1991). Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF-κB transcription factor and HIV-1. EMBO J. 10, 2247-2258.
49. STAIB, F., HUSSAIN, S.P., HOFSETH, L.J., WANG, X.W., and HARRIS, C.C. (2003). TP53 and liver carcinogenesis. Hum. Mutat. 21, 201-216.
50. TEOH, N., DELA PENA, A., and FARRELL, G. (2002). Hepatic ischemic preconditioning in mice is associated with activation of NF-κB, p38 kinase, and cell cycle entry. Hepatology 36, 94-102.
51. TEOH, N., LECLERCQ, I., PENA, A.D., and FARRELL, G. (2003). Low-dose TNF-α protects against hepatic ischemia-reperfusion injury in mice: Implications for preconditioning. Hepatology 37, 118-128.
52. TIETZE, M.K., WUESTEFELD, T., PAUL, Y., ZENDER, L., TRAUTWEIN, C., MANNS, M.P., and KUBlCKA, S. (2000). IκBα gene therapy in tumor necrosis factor-α- and chemotherapy-mediated apoptosis of hepatocellular carcinomas. Cancer Gene Ther. 7, 1315-1323.
53. TUVDENDORJ, D., OKETANI, M., IKEDA, R., KOHARA, K., KOMORIZONO, Y., ISHIBASHI, K., MUNKHTUVSHIN, N., and ARIMA, T. (2003). Aspirin induces hepatoma-derived cell apoptosis via a hydrogen peroxide-dependent pathway. Hepatol. Res. 26, 47-54.
54. VAN ANTWERP, D.J., MARTIN, S.J., KAFRI, T., GREEN, D.R., and VERMA, I.M. (1996). Suppression of TNF-α-induced apoptosis by NF-κB. Science 274, 787-789.
55. VOORHEES, P.M., DEES, E.C., O'NEIL, B., and ORLOWSKI, R.Z. (2003). The proteasome as a target for cancer therapy. Clin. Cancer Res. 9, 6316-6325.
56. WANG, C.Y., MAYO, M.W., and BALDWIN, A.S., Jr. (1996). TNF-α and cancer therapy-induced apoptosis: Potentiation by inhibition of NF-κB. Science 274, 784-787.
57. WANG, C.Y., CUSACK, J.C., JR., LIU, R., and BALDWIN, A.S., Jr. (1999). Control of inducible chemoresistance: Enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-κB. Nat. Med. 5, 412-417.
58. WEBBER, E.M., BRUIX, J., PIERCE, R.H., and FAUSTO, N. (1998). Tumor necrosis factor primes hepatocytes for DNA replication in the rat. Hepatology 28, 1226-1234.
59. XU, Y., BIALIK, S., JONES, B.E., IIMURO, Y., KITSIS, R.N., SRINIVASAN, A., BRENNER, D.A., and CZAJA, M.J. (1998). NF-κB inactivation converts a hepatocyte cell line TNF-α response from proliferation to apoptosis. Am. J. Physiol. 275, C1058-C1066.
60. YOONG, K.F., MCNAB, G., HUBSCHER, S.G., and ADAMS, D.H. (1998). Vascular adhesion protein-1 and ICAM-1 support the adhesion of tumor-infiltrating lymphocytes to tumor endothelium in human hepatocellular carcinoma. J. Immunol. 160, 3978-3988.